Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation.
Dig Liver Dis
; 51(8): 1117-1122, 2019 08.
Article
in En
| MEDLINE
| ID: mdl-31272935
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gastrointestinal Agents
/
Inflammatory Bowel Diseases
/
Drug Substitution
/
Infliximab
/
Antibodies, Monoclonal
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Language:
En
Journal:
Dig Liver Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2019
Type:
Article
Affiliation country:
Italy